1.

Enhancing the value of the sFlt-1/PlGF ratio for the prediction of preeclampsia: Cost analysis from the Belgian healthcare payers' perspective.

2.

Enhancing the value of the sFlt-1/PlGF ratio for the prediction of preeclampsia: Cost analysis from the Belgian healthcare payers' perspective.

3.

Enhancing the value of the sFlt-1/PlGF ratio for the prediction of preeclampsia: Cost analysis from the Belgian healthcare payers' perspective.

4.

Enhancing the value of the sFlt-1/PlGF ratio for the prediction of preeclampsia: Cost analysis from the Belgian healthcare payers' perspective.

5.

Enhancing the value of the sFlt-1/PlGF ratio for the prediction of preeclampsia: Cost analysis from the Belgian healthcare payers' perspective.

6.

Enhancing the value of the sFlt-1/PlGF ratio for the prediction of preeclampsia: Cost analysis from the Belgian healthcare payers' perspective.

7.

Enhancing the value of the sFlt-1/PlGF ratio for the prediction of preeclampsia: Cost analysis from the Belgian healthcare payers' perspective.

8.

Enhancing the value of the sFlt-1/PlGF ratio for the prediction of preeclampsia: Cost analysis from the Belgian healthcare payers' perspective.

9.

Enhancing the value of the sFlt-1/PlGF ratio for the prediction of preeclampsia: Cost analysis from the Belgian healthcare payers' perspective.

1.

Risk adjusted benchmarking of abdominoperineal excision for rectal adenocarcinoma in the context of the Belgian PROCARE improvement project.

2.

Risk adjusted benchmarking of abdominoperineal excision for rectal adenocarcinoma in the context of the Belgian PROCARE improvement project.

3.

Risk adjusted benchmarking of abdominoperineal excision for rectal adenocarcinoma in the context of the Belgian PROCARE improvement project.

4.

Risk adjusted benchmarking of abdominoperineal excision for rectal adenocarcinoma in the context of the Belgian PROCARE improvement project.

5.

Risk adjusted benchmarking of abdominoperineal excision for rectal adenocarcinoma in the context of the Belgian PROCARE improvement project.

6.

Risk adjusted benchmarking of abdominoperineal excision for rectal adenocarcinoma in the context of the Belgian PROCARE improvement project.

7.

Risk adjusted benchmarking of abdominoperineal excision for rectal adenocarcinoma in the context of the Belgian PROCARE improvement project.

8.

Risk adjusted benchmarking of abdominoperineal excision for rectal adenocarcinoma in the context of the Belgian PROCARE improvement project.

1.

Varicella paediatric hospitalisations in Belgium: a 1-year national survey.

2.

Varicella paediatric hospitalisations in Belgium: a 1-year national survey.

3.

Varicella paediatric hospitalisations in Belgium: a 1-year national survey.

4.

Varicella paediatric hospitalisations in Belgium: a 1-year national survey.

5.

Varicella paediatric hospitalisations in Belgium: a 1-year national survey.

6.

Varicella paediatric hospitalisations in Belgium: a 1-year national survey.

7.

Varicella paediatric hospitalisations in Belgium: a 1-year national survey.

1.

Acting one's age in physical exercise : do perceived age norms explain autonomous motivation among older adults?

2.

Acting one's age in physical exercise : do perceived age norms explain autonomous motivation among older adults?

1.

Long term outcome up to 30 years after the Mustard or Senning operation: a nationwide multicentre study in Belgium.

2.

Long term outcome up to 30 years after the Mustard or Senning operation: a nationwide multicentre study in Belgium.

3.

Long term outcome up to 30 years after the Mustard or Senning operation: a nationwide multicentre study in Belgium.

4.

Long term outcome up to 30 years after the Mustard or Senning operation: a nationwide multicentre study in Belgium.

5.

Long term outcome up to 30 years after the Mustard or Senning operation: a nationwide multicentre study in Belgium.

6.

Long term outcome up to 30 years after the Mustard or Senning operation: a nationwide multicentre study in Belgium.

7.

Long term outcome up to 30 years after the Mustard or Senning operation: a nationwide multicentre study in Belgium.

1.

Can we import quality tools? a feasibility study of European practice assessment in a country with less organised general practice

2.

Can we import quality tools? a feasibility study of European practice assessment in a country with less organised general practice

3.

Can we import quality tools? a feasibility study of European practice assessment in a country with less organised general practice

1.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

2.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

3.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

4.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

5.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

6.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

7.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

8.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

1.

Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.

2.

Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.

3.

Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.

4.

Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.

5.

Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.

6.

Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.

7.

Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.

1.

Testing of patients and coronavirus disease 2019 (COVID-19) infection before scheduled deliveries.

2.

Testing of patients and coronavirus disease 2019 (COVID-19) infection before scheduled deliveries.

3.

Testing of patients and coronavirus disease 2019 (COVID-19) infection before scheduled deliveries.

1.

High Job-Strain and ambulatory blood-pressure in middle-aged mec and women from the Belstress study